"The systemic hormonal contraceptive market is currently a $7bn market, with hormonal oral contracep
Added: (Mon May 18 2009)
Pressbox (Press Release) -
San Francisco, CA and London, UK; 18 May 2009: Women's Reproductive Disorders Therapeutics 2008-2018
Article Source: http://www.visiongain.com/Report.aspx?rid=340
Visiongain predicts that there is great potential for the women’s reproductive disorders therapeutics market from present onwards, as this new report Women’s Reproductive Disorders Therapeutics, 2008-2018 shows.
Oral Contraceptive Market
The systemic hormonal contraceptive market is currently a $7bn market, with hormonal oral contraceptives dominating the market for many years. The oral pills are increasingly facing competition from other routes of delivery. With patent expiration, several companies have begun manufacturing generic products. Hormonal contraceptives for women have become the benchmark for the safety and effectiveness of birth control methods.
Although hormonal contraceptives are already a very mature market, visiongain believes that there is still room for further growth. In addition, modern basic research has identified some completely new approaches for the contraceptives of the future. Hormonal oral contraceptives will continue to play an important role in birth control from 2008 to 2018.
Lifecycle Management and Product Line Extension
The hormonal oral contraceptive market is undergoing both lifecycle management and product line extension of existing products in the market. There are progestin-only preparations and combined preparations containing an oestrogen and a progestin. Bayer Schering is developing a pill containing various forms of progestin. Clinical studies show that the new drospirenone pill has an apparent therapeutic effect on premenstrual dysphoria - a particularly severe form of the premenstrual syndrome (PMS), as well as on acne. Pills are increasingly being developed with reduced oestrogen dosages. Visiongain evaluates the prospects for extended or continuous administration of oral contraceptives. It is becoming popular for the treatment of endometriosis, dysmenorrhoea and menstrual-associated symptoms.
Menopause and Hormone Replacement Therapy
HRT has been the subject of considerable discussion recently. In light of recent and current studies, visiongain provides comprehensive market information on HRT market prospects from 2008 to 2018.
Women’s Reproductive Disorders Therapeutics, 2008-2018 examines that market critically, through comprehensive primary and secondary research. In addition to consultation with industry opinion, this research involved a detailed study of policy documents, industrial reports and relevant news. Importantly, visiongain also applied techniques such as financial forecasting, SWOT analyses and qualitative projections. The result is a comprehensive market-based study with detailed financial analyses and informed opinion on the future of the women’s reproductive health market.
In particular, our new Women’s Reproductive Disorders Therapeutics, 2008-2018 report concentrates on the following essential aspects of that market:
• Overview of the women’s reproductive therapies market
• Key industrial players in the global women’s reproductive therapies market
• Forecasts of global market from 2008-2018, including forecasts of the leading therapeutic agents in this market area
• Forecasts for therapies in the seven leading pharmaceutical markets
• Drivers and opportunities in the global women’s reproductive therapies market
• Restraints and threats in the global women’s reproductive therapies market
• Primary research, with full interview transcripts
• Coverage of pipeline developments, with discussion of trends from the present onwards
Why You Should Buy This Report
In Women’s Reproductive Disorders Therapeutics, 2008-2018 you will receive the following essential information for understanding the women’s reproductive disorders therapeutics market and industry:
• The value of the women’s reproductive disorders therapeutics market and its principal market segments from 2008 to 2018
• Which current or future therapies that will drive the market for women’s reproductive disorders therapeutics from 2008 to 2018, with detailed sales forecasts
• Market drivers and restraints, including a comprehensive SWOT analysis for women’s reproductive disorders therapeutics
• The companies involved in the market and their business strategies
This Report would be Useful to the Following Professionals, Amongst Others:
• Business managers of pharmaceutical industry related to women’s reproductive disorders therapeutics
• Researchers, analysts and academics interested in women’s reproductive disorders therapeutics
• Senior staff in healthcare authorities relevant to women’s reproductive disorders therapeutics
• Investors in the pharmaceutical industry relevant to women’s reproductive disorders therapeutics
• Other interested business managers of multinational companies relevant to women’s reproductive disorders therapeutics
• Other business managers of domestic companies
• Academics, researchers and media
Visiongain ltd.
4th Floor,
BSG House,
226 236 City Road,
London
EC1V 2QY
United Kingdom
Telephone: +44 (0) 20 7336 6100
Fax: +44 (0) 20 7549 9930
info@visiongainglobal.com
Or Visit at: http://www.visiongain.com/Report.aspx?rid=340
Or http://www.visiongain.com
Or
Contact Person
Suvitha Damodaran
suvitha.damodaran@visiongainglobal.com
Direct Line: +44 (0)20 7549 9946
+44 (0)20 7336 6100